P/E ratio for Karyopharm Therapeutics (KPTI)
P/E ratio as of April 2024 (TTM): -0.8333
According to Karyopharm Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.833333. At the end of 2022 the company had a P/E ratio of -1.67.
P/E ratio history for Karyopharm Therapeutics from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.67 | -56.76% |
| 2021 | -3.87 | -31.69% |
| 2020 | -5.67 | -4.46% |
| 2019 | -5.93 | 98.26% |
| 2018 | -2.99 | -12.69% |
| 2017 | -3.43 | 6.87% |
| 2016 | -3.21 | -19.61% |
| 2015 | -3.99 | -74.3% |
| 2014 | -15.5 | 540.39% |
| 2013 | -2.43 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 36.1 | -4,430.93% | 🇺🇸 USA |
 Merck MRK | 71.4 | -8,671.44% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.2 | -1,449.32% | 🇺🇸 USA |
 Exelixis EXEL | 83.8 | -10,151.54% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.